{"id":681795,"date":"2023-12-19T11:36:02","date_gmt":"2023-12-19T11:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=681795"},"modified":"2023-12-19T11:36:02","modified_gmt":"2023-12-19T11:36:02","slug":"parkinsons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-abbvie-pfizer-novartis-f-roche-kissei-pharma-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/parkinsons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-abbvie-pfizer-novartis-f-roche-kissei-pharma-astrazeneca_681795.html","title":{"rendered":"Parkinson\u2019s Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1702900923.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Parkinson&rsquo;s Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca\" src=\"https:\/\/www.abnewswire.com\/uploads\/1702900923.jpeg\" alt=\"Parkinson&rsquo;s Disease Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Parkinson\u2019s Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson\u2019s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\">The Parkinson&rsquo;s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Parkinson&rsquo;s Disease Pipeline Insight, 2023<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson&rsquo;s Disease Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Parkinson&rsquo;s Disease Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Companies across the globe are diligently working toward developing novel Parkinson&rsquo;s Disease treatment therapies with a considerable amount of success over the years.&nbsp;<\/li>\n<li>Parkinson&rsquo;s Disease companies working in the treatment market are <strong>FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others,<\/strong> are developing therapies for the Parkinson&rsquo;s Disease treatment&nbsp;<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Emerging Parkinson&rsquo;s Disease therapies in the different phases of clinical trials are- <strong>KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others<\/strong> are expected to have a significant impact on the Parkinson&rsquo;s Disease market in the coming years.&nbsp;&nbsp;&nbsp;<\/li>\n<li><strong>In December 2023, Gain Therapeutics,<\/strong> a biotechnology company situated in the United States, has released preclinical findings showcasing the promise of small molecule allosteric regulators in addressing beta-galactosidase-1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis.<\/li>\n<li><strong>In December 2023, Vanqua Bio<\/strong> disclosed plans to commence clinical trials in the first quarter of 2024, evaluating the investigational drug <strong>VQ-101<\/strong> as a potential treatment for Parkinson&#8217;s disease linked to GBA1 mutations.<\/li>\n<li><strong>In March 2022, Neuron23<\/strong> secured a funding of $100 million to progress in Parkinson&#8217;s disease therapy. Their plan involves initiating trials for <strong>NEU-723<\/strong>, a potential treatment for Parkinson&#8217;s disease, by the year&#8217;s end.<\/li>\n<li><strong>In January 2022, The clinical-stage biotechnology company ABL Bio Inc.<\/strong> has partnered with Sanofi through a global licensing agreement to jointly develop and market a therapy for Parkinson&#8217;s disease and other potential medical uses. The treatment, <strong>ABL301<\/strong>, is a bispecific antibody in the preclinical stage designed to target alpha-synuclein and the insulin-like growth factor 1 receptor (IGF1R) while enhancing its ability to penetrate the blood-brain barrier.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Parkinson&rsquo;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Parkinson&#8217;s disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson&#8217;s disease experience difficulties with movement control.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Parkinson&rsquo;s Disease Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Parkinson&rsquo;s Disease Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>KM-819:<\/strong> FAScinate Therapeutics<\/li>\n<li><strong>Prasinezumab:<\/strong> Hoffmann-La Roche<\/li>\n<li><strong>P2B001:<\/strong> Pharma Two B Ltd.<\/li>\n<li><strong>NPT1220-478:<\/strong> Neuropore Therapies, Inc.<\/li>\n<li><strong>Dapansutrile:<\/strong> Olatec Therapeutics<\/li>\n<li><strong>UCB7853:<\/strong> UCB Biopharma<\/li>\n<li><strong>UB-312:<\/strong> Vaxxinity<\/li>\n<li><strong>Emrusolmin:<\/strong> Modag<\/li>\n<li><strong>PT320:<\/strong> Peptron<\/li>\n<li><strong>KDT-3594<\/strong>: Kissei Pharmaceutical<\/li>\n<li><strong>Tavapadon:<\/strong> Cerevel Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Parkinson&rsquo;s Disease Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Parkinson&rsquo;s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Inhalation<\/li>\n<li>Inhalation\/Intravenous\/Oral<\/li>\n<li>Intranasal<\/li>\n<li>Intravenous<\/li>\n<li>Intravenous\/ Subcutaneous<\/li>\n<li>NA<\/li>\n<li>Oral<\/li>\n<li>Oral\/intranasal\/subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Parkinson&rsquo;s Disease Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Parkinson&rsquo;s Disease Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Antibody<\/li>\n<li>Antisense oligonucleotides<\/li>\n<li>Immunotherapy<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptides<\/li>\n<li>Protein<\/li>\n<li>Recombinant protein<\/li>\n<li>Small molecule<\/li>\n<li>Stem Cell<\/li>\n<li>Vaccine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Parkinson&rsquo;s Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Parkinson&rsquo;s Disease Assessment by Product Type<\/li>\n<li>Parkinson&rsquo;s Disease By Stage and Product Type<\/li>\n<li>Parkinson&rsquo;s Disease Assessment by Route of Administration<\/li>\n<li>Parkinson&rsquo;s Disease By Stage and Route of Administration<\/li>\n<li>Parkinson&rsquo;s Disease Assessment by Molecule Type<\/li>\n<li>Parkinson&rsquo;s Disease by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Parkinson&rsquo;s Disease Report covers around 150+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Further Parkinson&rsquo;s Disease product details are provided in the report. Download the Parkinson&rsquo;s Disease pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Parkinson&rsquo;s Disease therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Parkinson&rsquo;s Disease Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Parkinson&rsquo;s Disease are &#8211;<strong><em> Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Parkinson&rsquo;s Disease Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Parkinson&rsquo;s Disease pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson&rsquo;s Disease with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson&rsquo;s Disease Treatment.<\/li>\n<li>Parkinson&rsquo;s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Parkinson&rsquo;s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson&rsquo;s Disease market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Parkinson&rsquo;s Disease drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Parkinson&rsquo;s Disease Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing prevalence of Parkinson&rsquo;s Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson&rsquo;s Disease Market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Parkinson&rsquo;s Disease Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>However, lack of awareness and delayed diagnosis, side effects associated with Parkinson&rsquo;s disease treatment drugs and other factors are creating obstacles in the Parkinson&rsquo;s Disease Market growth.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Parkinson&rsquo;s Disease Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Parkinson&rsquo;s Disease Companies:<\/strong> FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others<\/li>\n<li><strong>Key Parkinson&rsquo;s Disease Therapies:<\/strong> KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others<\/li>\n<li><strong>Parkinson&rsquo;s Disease Therapeutic Assessment:<\/strong> Parkinson&rsquo;s Disease current marketed and Parkinson&rsquo;s Disease emerging therapies<\/li>\n<li><strong>Parkinson&rsquo;s Disease Market Dynamics: Parkinson&rsquo;s Disease market drivers and Parkinson&rsquo;s Disease market barriers&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/parkinsons-disease-pipeline-insights?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Parkinson&rsquo;s Disease Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Parkinson&rsquo;s Disease Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Parkinson&rsquo;s Disease Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Parkinson&rsquo;s Disease Overview<\/p>\n<p style=\"text-align: justify;\">4. Parkinson&rsquo;s Disease- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Parkinson&rsquo;s Disease Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Parkinson&rsquo;s Disease Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Parkinson&rsquo;s Disease Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Parkinson&rsquo;s Disease Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Parkinson&rsquo;s Disease Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Parkinson&rsquo;s Disease Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Parkinson&rsquo;s Disease Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Parkinson&rsquo;s Disease Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Parkinson&rsquo;s Disease Key Products<\/p>\n<p style=\"text-align: justify;\">15. Parkinson&rsquo;s Disease Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Parkinson&rsquo;s Disease Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Parkinson&rsquo;s Disease Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Parkinson&rsquo;s Disease Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=parkinsons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-abbvie-pfizer-novartis-f-roche-kissei-pharma-astrazeneca\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=parkinsons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-abbvie-pfizer-novartis-f-roche-kissei-pharma-astrazeneca\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Parkinson\u2019s Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson\u2019s Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/parkinsons-disease-pipeline-and-clinical-trials-assessment-2023-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-abbvie-pfizer-novartis-f-roche-kissei-pharma-astrazeneca_681795.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-681795","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/681795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=681795"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/681795\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=681795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=681795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=681795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}